Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

The Human Epidermal Growth Factor Receptor 2 (Her2, ErbB2 or Neu) is overexpressed in about 20 – 25% of breast cancers and is causally linked to oncogenesis, providing opportunities for targeted therapy. Trastuzumab (Herceptin(™), Genentech Inc, San Francisco, CA), a humanized monoclonal antibody ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Tameka A., Luan, Haitao, Clubb, Robert J., Naramura, Mayumi, Band, Vimla, Raja, Srikumar M., Band, Hamid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243087/
https://www.ncbi.nlm.nih.gov/pubmed/22190870
http://dx.doi.org/10.4103/1477-3163.90442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243087/
https://www.ncbi.nlm.nih.gov/pubmed/22190870
http://dx.doi.org/10.4103/1477-3163.90442

Ejemplares similares